Aeglea BioTherapeutics announces 15% workforce reduction, COO departure

Aeglea BioTherapeutics announced an update to its corporate structure. These changes are in addition to the restructuring process that was initiated in August 2022 and are intended to further streamline the organization, create operational efficiencies to support near- and long-term objectives and maximize the value of the company’s two clinical programs. As part of these additional changes, the workforce of the company has been further reduced by approximately 15%. Aeglea is also halting the preclinical work on the Cystinuria and other unnamed pipeline programs. The company will evaluate potential strategic options for these programs in order to maximize value. In conjunction with these announcements, Cortney Caudill has been promoted from senior vice president of technical operations to chief product officer, effective January 6, 2023. In this expanded role, Caudill will be a strategic leader, team supervisor, and internal advocate for Aeglea’s clinical programs, helping the company focus on key deliverables and resource allocation for both Homocystinuria and Arginase 1 Deficiency programs. In addition, Leslie Sloan, Ph.D., will be departing from her role as COO.